Kazfluvir

**Kazfluvir** is an egg-derived, allantoic split inactivated trivalent seasonal influenza vaccine developed and manufactured by the Research Institute for Biological Safety Problems in Kazakhstan. The vaccine contains 15 micrograms of hemagglutinin from each included influenza strain per 0.5 mL dose. The evaluated 2016–2017 formulation included A/California/7/2009 H1N1pdm09, A/Hong Kong/4801/2014 H3N2, and B/Brisbane/60/2008 strains. Viruses are inactivated with beta-propiolactone and split with Triton X-100. It is formulated without thiomersal, preservatives, or adjuvants and is intended for prevention of seasonal influenza through induction of strain-specific immune responses against viral hemagglutinin.

Brand names

Kazfluvir

Other names

allantoic split inactivated seasonal influenza vaccineRIBSP vaccinetrivalent inactivated influenza vaccineVSI